Standout Papers

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial 2024 202657
  1. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial (2024)
    Egbert F. Smit, Enriqueta Felip et al. The Lancet Oncology

Immediate Impact

1 from Science/Nature 64 standout
Sub-graph 1 of 22

Citing Papers

H3K18 Lactylation Potentiates Immune Escape of Non–Small Cell Lung Cancer
2024 Standout
FASN Inhibition Decreases MHC-I Degradation and Synergizes with PD-L1 Checkpoint Blockade in Hepatocellular Carcinoma
2024 Standout
2 intermediate papers

Works of Andreas Saltos being referenced

Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer
2019
Clinical associations of mucin 1 in human lung cancer and precancerous lesions
2018

Author Peers

Author Last Decade Papers Cites
Andreas Saltos 381 252 183 42 609
Susan Chang 62 97 150 24 517
Yi Cheng 388 308 162 27 687
Yangyang Xu 291 127 207 34 590
Vyshak Alva Venur 405 475 134 60 708
Weiwei Jin 316 201 159 46 612
Yoshinori Kodama 183 147 219 51 661
Reena Thomas 222 186 140 39 677
Ilaria Maggio 362 214 111 30 682
Myra E. van Linde 182 151 213 34 690
Eric Burton 236 145 206 26 564

All Works

Loading papers...

Rankless by CCL
2026